| Recommendations for diagnosis and treatment of methemoglobinemia A Iolascon, P Bianchi, I Andolfo, R Russo, W Barcellini, E Fermo, G Toldi, ... American journal of hematology 96 (12), 1666-1678, 2021 | 93 | 2021 |
| Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation JACC: CardioOnc 3 (2), 250-259, 2021 | 79* | 2021 |
| Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies R Mohty, R Dulery, AH Bazarbachi, M Savani, RA Hamed, A Bazarbachi, ... Blood Cancer Journal 11 (7), 126, 2021 | 33 | 2021 |
| Impact of adding antithymocyte globulin to posttransplantation cyclophosphamide in haploidentical stem-cell transplantation J El-Cheikh, R Devillier, R Dulery, R Massoud, F Al Chami, N Ghaoui, ... Clinical Lymphoma Myeloma and Leukemia 20 (9), 617-623, 2020 | 26 | 2020 |
| Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma HB Alkhateeb, R Mohty, P Greipp, R Bansal, M Hathcock, A Rosenthal, ... Blood cancer journal 12 (7), 113, 2022 | 24 | 2022 |
| Cancer in the Arab world HO Al-Shamsi, IH Abu-Gheida, F Iqbal, A Al-Awadhi Springer Nature, 2022 | 24 | 2022 |
| CD34+-selected stem cell “Boost” for poor graft function after allogeneic hematopoietic stem cell transplantation R Mohty, E Brissot, G Battipaglia, A Ruggeri, S Sestili, C Mediavilla, ... Current Research in Translational Medicine 67 (3), 112-114, 2019 | 22 | 2019 |
| Infectious complications after post‐transplantation cyclophosphamide and anti‐thymocyte globulin‐based haploidentical stem cell transplantation R Mohty, E Brissot, G Battipaglia, A Ruggeri, R Dulery, A Bonnin, ... British Journal of Haematology 187 (3), e64-e68, 2019 | 20 | 2019 |
| Impact of cyclosporine A concentration on acute graft‐vs‐host disease incidence after haploidentical hematopoietic cell transplantation N Stocker, R Dulery, G Battipaglia, E Brissot, C Médiavilla, S Sestili, ... European journal of haematology 103 (1), 10-17, 2019 | 20 | 2019 |
| New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia R Mohty, R El Hamed, E Brissot, A Bazarbachi, M Mohty Haematologica 108 (2), 321, 2023 | 18 | 2023 |
| Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies Z Peric, R Mohty, J Bastos, E Brissot, G Battipaglia, R Belhocine, S Sestili, ... Bone Marrow Transplantation 55 (4), 763-772, 2020 | 18 | 2020 |
| Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors R Mohty, J Gauthier Bone Marrow Transplantation 56 (11), 2630-2636, 2021 | 16 | 2021 |
| Impact of gut fungal and bacterial communities on the outcome of allogeneic hematopoietic cell transplantation F Malard, A Lavelle, G Battipaglia, B Gaugler, R Dulery, E Brissot, ... Mucosal Immunology 14 (5), 1127-1132, 2021 | 15 | 2021 |
| CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma R Mohty, MA Kharfan-Dabaja Therapeutic Advances in Hematology 13, 20406207221142133, 2022 | 14 | 2022 |
| The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel … K Rejeski, Y Wang, O Albanyan, J Munoz, P Sesques, G Iacoboni, ... American journal of hematology 98 (11), 1699-1710, 2023 | 11 | 2023 |
| The CAR-hematotox score identifies patients at high risk for hematological toxicity, infections and poor clinical outcomes following brexucabtagene autoleucel in relapsed … K Rejeski, Y Wang, O Albanyan, JL Munoz, P Sesques, G Iacoboni, ... Blood 140 (Supplement 1), 651-653, 2022 | 10 | 2022 |
| Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease R Mohty, R Al Hamed, A Bazarbachi, E Brissot, A Nagler, A Zeidan, ... Journal of Hematology & Oncology 15 (1), 124, 2022 | 7 | 2022 |
| Allogeneic haematopoietic cell transplantation for myelofibrosis: a real‐life perspective M Savani, R Dulery, AH Bazarbachi, R Mohty, E Brissot, F Malard, ... British Journal of Haematology 195 (4), 495-506, 2021 | 7 | 2021 |
| Emerging role of autologous CD19 CAR T-cell therapies in the second-line setting for large B-cell lymphoma: A game changer? R Mohty, MA Moustafa, M Aljurf, H Murthy, MA Kharfan-Dabaja Hematology/Oncology and Stem Cell Therapy 15 (3), 73-80, 2022 | 6 | 2022 |
| Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality K Rejeski, Y Wang, DK Hansen, G Iacoboni, E Bachy, R Bansal, ... Blood Advances 8 (8), 1857-1868, 2024 | 5 | 2024 |
Radwan MassoudUniversitätsklinikum Hamburg-Eppendorf (UKE)在 uke.de 的电子邮件经过验证
Radwan MassoudUniversitätsklinikum Hamburg-Eppendorf (UKE)在 uke.de 的电子邮件经过验证
Nicolas StockerDepartment of Clinical Hematology, Saint-Antoine Hospital, Paris, France在 inserm.fr 的电子邮件经过验证